Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ISRCTN12491684) titled 'PATHWAYS TRIAL, PATHWAYS HORIZON INTENSIVE, PATHWAYS CONNECT' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Open (masking not used)
Control: Active
Assignment: PATHWAYS TRIAL: Immediate vs Delayed (12 months) GnRHa Treatment. 226 participants total. PATHWAYS HORIZON INTENSIVE: Non-randomised, intensive observational control cohort broadly matched to PATHWAYS TRIAL participants. 300 participants total. PATHWAYS CONNECT: 150 participants from TRIAL, 100 participants from HORIZON INTENSIVE. 250 participants total.
Purpose: Treatment
Primary Sponsor: Kin...